BIOSTATISTICS IN CLINICAL TRIALS
Kate Francis, Biostatistician (Snr Research Officer)
Murdoch Children’s Research Institute &
Honorary Research Fellow,
Department of Paediatrics, University of Melbourne &
Affiliate Biostatistician,
The Royal Children’s Hospital,
Melbourne, Australia
RESEARCHER PROFILE
Filmed in Melbourne, Australia | July 2025
Kate Francis is a biostatistician with the Murdoch Children’s Research Institute (MCRI), an Honorary (Senior Fellow) within Department of Paediatrics, the University of Melbourne and Affiliate biostatistician with Royal Children’s Hospital in Narrm (Melbourne), Australia.
As a biostatistician working in research and clinical settings, she plays a vital role in ensuring all projects adhere to best practice guidelines and are transparently reported. She has served as the lead statistician for the analysis of clinical trials across a broad range of subject areas, including neonatal resuscitation, BCG for allergy and infection, convulsive status epilepticus and her work has been published in the top journals such as The New England Journal of Medicine, JAMA, and The Lancet. Most recently she was awarded the 2025 Excellence in Trial Statistics Award for her work on the PLUSS trial.
Kate is also an expert in the measurement of adolescent health behaviours, determinants, and outcomes and this was recognised with her invitation to be a commissioner for the second Lancet Commission on Adolescent Health and Wellbeing which was recently released at the 2025 World Health Assembly meeting.
Kate believes in the importance of gender equity, diversity, and inclusion and was key team member in helping MCRI achieve bronze accreditation in the Science in Australia Gender Equity (SAGE) program.
Source: Supplied
-
Professor Matthew Kiernan
BRAIN AND MIND CENTRE
@ UNIVERSITY OF SYDNEY, NEW SOUTH WALES AUSTRALIA -
Dr Ryan O’Hare Doig
NEIL SACHSE CENTRE FOR SPINAL CORD RESEARCH (SAHMRI)
SOUTH AUSTRALIA
AUSTRALIA -
CASE STUDY Next Generation Condom Contraception
Eudaemon Technologies, an early-stage medtech company with a focus on sexual reproductive health, is developing a hydrogel condom to address the need for a better feeling, next generation condom, with the potential to improve user experience and address issues with traditional latex condoms.
“Over 1 million STI’s being diagnosed every day and up to 120 million unplanned pregnancies every year result in a $60 billion health burden across the globe”, says Co-Founder and Executive Director of Operations, Dr Simon Cook.
Formed in 2018, the company focuses on developing tough hydrogels as an alternative to address issues with odour, colour, and taste commonly associated with latex condoms. This technology can be loaded with small molecule drugs for flavours or anti-STI compounds, and was developed in response to a grant from the Bill and Melinda Gates Foundation to address unplanned pregnancies and STIs.
